Joel D Schilling

List of Publications by Year
in descending order

60	4,974	159585 30	138484 58
papers	citations	h-index	g-index

61	61	61	8453
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Improvements in Extracorporeal Membrane Oxygenation for Primary Graft Failure After Heart Transplant. Annals of Thoracic Surgery, 2023, 115, 751-757.	1.3	4
2	Cardiac allograft rejection in the current era of continuous flow left ventricular assist devices. Journal of Thoracic and Cardiovascular Surgery, 2022, 163, 124-134.e8.	0.8	8
3	Competing Risks to Transplant in Bridging With Continuous-flow Left Ventricular Assist Devices. Annals of Thoracic Surgery, 2022, 114, 1276-1283.	1.3	5
4	Derivation of extra-embryonic and intra-embryonic macrophage lineages from human pluripotent stem cells. Development (Cambridge), 2022, 149, .	2.5	2
5	The Power of Singleâ€Cell Analysis for the Study of Liver Pathobiology. Hepatology, 2021, 73, 437-448.	7.3	19
6	CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder. American Journal of Transplantation, 2021, 21, 809-814.	4.7	44
7	Macrophages Fuel Skeletal Muscle Regeneration. Immunometabolism, 2021, 3, .	1.6	2
8	Dynamic Shifts in the Composition of Resident and Recruited Macrophages Influence Tissue Remodeling in NASH. Cell Reports, 2021, 34, 108626.	6.4	164
9	30 Years of Heart Transplant: Outcomes After Mechanical Circulatory Support From a Single Center. Annals of Thoracic Surgery, 2021, , .	1.3	7
10	Trehalose causes low-grade lysosomal stress to activate TFEB and the autophagy-lysosome biogenesis response. Autophagy, 2021, 17, 3740-3752.	9.1	54
11	Comprehensive analysis of liver macrophage composition by flow cytometry and immunofluorescence in murine NASH. STAR Protocols, 2021, 2, 100511.	1.2	20
12	Paradoxical outcome of heart transplantation associated with institutional case volume. Clinical Transplantation, 2021, 35, e14471.	1.6	2
13	Trimming the Fat in HFpEF. JACC Basic To Translational Science, 2020, 5, 928-930.	4.1	1
14	A Short Bridge Over a Wide River: The Role of Extracorporeal Membrane Oxygenation in Older Adults With Cardiogenic Shock. Journal of Cardiac Failure, 2020, 26, 1090-1092.	1.7	3
15	Inhibition of Fatty Acid Oxidation Promotes Macrophage Control of Mycobacterium tuberculosis. MBio, 2020, 11, .	4.1	39
16	High-protein diets increase cardiovascular risk by activating macrophage mTOR to suppress mitophagy. Nature Metabolism, 2020, 2, 110-125.	11.9	85
17	Right Heart Failure While on Left Ventricular Assist Device Support Is Associated with Primary Graft Dysfunction. ASAIO Journal, 2020, 66, 1137-1141.	1.6	11
18	Frontline Science: Acyl-CoA synthetase 1 exacerbates lipotoxic inflammasome activation in primary macrophages. Journal of Leukocyte Biology, 2019, 106, 803-814.	3.3	22

#	Article	IF	Citations
19	Be Still My Beating Heart: Should Heart Rate Be a Target of Therapy After Heart Transplantation?. Journal of Cardiac Failure, 2019, 25, 257-258.	1.7	1
20	The Interplay Between Tissue Niche and Macrophage Cellular Metabolism in Obesity. Frontiers in Immunology, 2019, 10, 3133.	4.8	42
21	TFEB activation in macrophages attenuates postmyocardial infarction ventricular dysfunction independently of ATG5-mediated autophagy. JCI Insight, 2019, 4, .	5.0	39
22	Immunomodulatory role of nonneuronal cholinergic signaling in myocardial injury. JCI Insight, 2019, 4, .	5.0	19
23	PGC1Î² Organizes the Osteoclast Cytoskeleton by Mitochondrial Biogenesis and Activation. Journal of Bone and Mineral Research, 2018, 33, 1114-1125.	2.8	48
24	Intersection of Pulmonary Hypertension and Right Ventricular Dysfunction in Patients on Left Ventricular Assist Device Support. Circulation: Heart Failure, 2018, 11, e004255.	3.9	31
25	Sildenafil in Left Ventricular Assist Device Is Safe and Well-Tolerated. ASAIO Journal, 2018, 64, 280-281.	1.6	20
26	The Hemodynamic Profile of GI Bleeding in Continuous-Flow LVADs: Is it All About the Right Ventricle?. Journal of Cardiac Failure, 2018, 24, 494-495.	1.7	0
27	PPARÎ³ Deficiency Suppresses the Release of IL-1Î² and IL-1Î± in Macrophages via a Type 1 IFNâ€“Dependent Mechanism. Journal of Immunology, 2018, 201, 2054-2069.	0.8	20
28	A novel genetic marker of decreased inflammation and improved survival after acute myocardial infarction. Basic Research in Cardiology, 2018, 113, 38.	5.9	58
29	Modulation of subsets of cardiac B lymphocytes improves cardiac function after acute injury. JCI Insight, 2018, 3, .	5.0	63
30	Exploiting macrophage autophagy-lysosomal biogenesis as a therapy for atherosclerosis. Nature Communications, 2017, 8, 15750.	12.8	258
31	Dousing fire with gasoline: interplay between lysosome damage and the NLRP3 inflammasome. Focus on â€œNLRP3 inflammasome signaling is activated by low-level lysosome disruption but inhibited by extensive lysosome disruption: roles for K+ efflux and Ca2+ influxâ€• American Journal of Physiology - Cell Physiology, 2016, 311, C81-C82.	4.6	5
32	Glutamine Modulates Macrophage Lipotoxicity. Nutrients, 2016, 8, 215.	4.1	35
33	Slicing Into Human Translational Cardiovascular Biology. JACC Basic To Translational Science, 2016, 1, 168-169.	4.1	0
34	Integrating immunometabolism and macrophage diversity. Seminars in Immunology, 2016, 28, 417-424.	5.6	137
35	PPAR-Î³ regulates pharmacological but not physiological or pathological osteoclast formation. Nature Medicine, 2016, 22, 1203-1205.	30.7	29
36	Metabolic Reprogramming Mediated by the mTORC2-IRF4 Signaling Axis Is Essential for Macrophage Alternative Activation. Immunity, 2016, 45, 817-830.	14.3	453

#	Article	IF	Citations
37	Inhibition of mTOR reduces lipotoxic cell death in primary macrophages through an autophagy-independent mechanism. Journal of Leukocyte Biology, 2016, 100, 1113-1124.	3.3	27
38	The Mitochondria in Diabetic Heart Failure: From Pathogenesis to Therapeutic Promise. Antioxidants and Redox Signaling, 2015, 22, 1515-1526.	5.4	76
39	Prognostic utility of novel biomarkers of cardiovascular stress in patients with aortic stenosis undergoing valve replacement. Heart, 2015, 101, 1382-1388.	2.9	90
40	Treatment of Secondary Pulmonary Hypertension with Bosentan after Left Ventricular Assist Device Implantation. Cardiovascular Therapeutics, 2015, 33, 50-55.	2.5	25
41	Pre-Operative Right Ventricular Dysfunction Is Associated With Gastrointestinal Bleeding in Patients Supported With Continuous-Flow LeftÂVentricular Assist Devices. JACC: Heart Failure, 2015, 3, 956-964.	4.1	63
42	Distinct Lysosome Phenotypes Influence Inflammatory Function in Peritoneal and Bone Marrow-Derived Macrophages. International Journal of Inflammation, 2014, 2014, 1-9.	1.5	15
43	Lysosomes Integrate Metabolic-Inflammatory Cross-talk in Primary Macrophage Inflammasome Activation. Journal of Biological Chemistry, 2014, 289, 9158-9171.	3.4	106
44	Embryonic and Adult-Derived Resident Cardiac Macrophages Are Maintained through Distinct Mechanisms at Steady State and during Inflammation. Immunity, 2014, 40, 91-104.	14.3	1,120
45	Distinct macrophage lineages contribute to disparate patterns of cardiac recovery and remodeling in the neonatal and adult heart. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16029-16034.	7.1	576
46	Diabetic Cardiomyopathy: Distinct and Preventable Entity or Inevitable Consequence?. Current Cardiovascular Risk Reports, 2014, 8, 1.	2.0	1
47	Hemolysis in left ventricular assist device: A retrospective analysis of outcomes. Journal of Heart and Lung Transplantation, 2014, 33, 44-50.	0.6	84
48	TLR4 Activation Under Lipotoxic Conditions Leads to Synergistic Macrophage Cell Death through a TRIF-Dependent Pathway. Journal of Immunology, 2013, 190, 1285-1296.	0.8	49
49	Palmitate and Lipopolysaccharide Trigger Synergistic Ceramide Production in Primary Macrophages. Journal of Biological Chemistry, 2013, 288, 2923-2932.	3.4	134
50	Macrophages modulate cardiac function in lipotoxic cardiomyopathy. American Journal of Physiology - Heart and Circulatory Physiology, 2012, 303, H1366-H1373.	3.2	39
51	Antibody-Mediated Rejection of the Heart in the Setting of Autoimmune Demyelinating Polyneuropathy: A Case Report and Review of the Literature. Case Reports in Cardiology, 2012, 2012, 1-4.	0.2	0
52	Diabetic Cardiomyopathy. Heart Failure Clinics, 2012, 8, 619-631.	2.1	98
53	The PGC-1 cascade as a therapeutic target for heart failure. Journal of Molecular and Cellular Cardiology, 2011, 51, 578-583.	1.9	92
54	Toll-Like Receptor-Mediated Inflammatory Signaling Reprograms Cardiac Energy Metabolism by Repressing Peroxisome Proliferator-Activated Receptor Î³ Coactivator-1 Signaling. Circulation: Heart Failure, 2011, 4, 474-482.	3.9	111

#	Article	IF	Citations
55	Right Coronary Artery to Coronary Sinus Fistula by Transesophageal Echocardiogram, Cardiac Magnetic Resonance Imaging, and Coronary Angiography. Clinical Cardiology, 2009, 32, E29-30.	1.8	2
56	CD14- and Toll-Like Receptor-Dependent Activation of Bladder Epithelial Cells by Lipopolysaccharide and Type 1 PiliatedEscherichia coli. Infection and Immunity, 2003, 71, 1470-1480.	2.2	136
57	Toll-like receptor 4 on stromal and hematopoietic cells mediates innate resistance to uropathogenic Escherichia coli. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 4203-4208.	7.1	181
58	RECENT ADVANCES IN THE MOLECULAR BASIS OF PATHOGEN RECOGNITION AND HOST RESPONSES IN THE URINARY TRACT. International Reviews of Immunology, 2002, 21, 291-304.	3.3	6
59	Effect of Trimethoprim-Sulfamethoxazole on Recurrent Bacteriuria and Bacterial Persistence in Mice Infected with Uropathogenic Escherichia coli. Infection and Immunity, 2002, 70, 7042-7049.	2.2	145
60	Recent advances into the pathogenesis of recurrent urinary tract infections: the bladder as a reservoir for uropathogenic Escherichia coli. International Journal of Antimicrobial Agents, 2002, 19, 457-460.	2.5	43